Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma

The mTOR inhibitor everolimus is currently approved for the treatment of renal cell carcinoma (RCC) and several Toll-like receptor 9 (TLR9) agonists, including immunomodulatory oligonucleotides (IMOs), have been tested for their therapeutic potential against advanced RCC. However, no clinical trials...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Rosa, Roberta, Damiano, Vincenzo, Formisano, Luigi, Nappi, Lucia, Marciano, Roberta, Veneziani, Bianca Maria, De Placido, Sabino, Bianco, Roberto
Format: Artigo
Sprache:Inglês
Veröffentlicht: Landes Bioscience 2013
Schlagworte:
Author's View
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3782521/
https://ncbi.nlm.nih.gov/pubmed/24083076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.25123
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge